Single dose radiotherapy effective in treating breast cancer

Organisation: Position: Deadline Date: Location:

A pioneering breast cancer therapy developed by University College London (UCL) clinicians, which requires just one shot of radiotherapy rather than conventional weeks-long treatment, has proven to be as effective for most women in treating the disease. The findings of the large international randomised tria confirm the long-term effectiveness of Targeted Intraoperative Radiotherapy (TARGIT-IORT): a breast cancer treatment which is increasingly available throughout the world.

TARGIT-IORT is delivered immediately after lumpectomy (tumour removal), via a small ball-shaped device placed inside the breast, directly where the cancer had been. The single-dose treatment lasts for around 20 to 30 minutes and replaces the need for extra hospital visits, benefiting both patient safety and well-being.

Conventional external beam radiotherapy (EBRT) is delivered from outside the body via a radiotherapy machine (linear accelerator), and consists of a daily treatment session (known as fractions) to the whole breast, over a period between three to six weeks. Each of these treatments is given over a few minutes, but requires 15 to 30 hospital visits, which could be a significant distance from where the patient lives.

To establish TARGIT-IORT’s long-term effectiveness, 2,298 women aged 45 or over with invasive ductal carcinoma (breast cancer) and a tumour of up to 3.5cm in size, were randomly assigned to receive either TARGIT-IORT or the traditional EBRT.

This large clinical trial, designed and run from UCL, involved 32 hospitals and medical centres in ten countries: the UK, France, Germany, Italy, Norway, Poland, Switzerland, the US, Canada and Australia. The trial started in March 2000, which has enabled researchers to publish these long-term results.

The findings show that with TARGIT-IORT therapy, eight out of every ten patients had no need for any further post-operative radiotherapy treatments. There was also no detriment to survival and no increase in the likelihood of the cancer returning.
In addition, with TARGIT-IORT, significantly fewer women died from causes other than breast cancer. Previous studies have shown that TARGIT-IORT has fewer radiation-related side effects compared with conventional whole breast radiotherapy, with less pain, better cosmetic outcome and a better quality of life.

Lead author, Professor Jayant Vaidya, (professor of surgery and oncology, UCL surgery & interventional science), said: “With TARGIT-IORT, women can have their surgery and radiation treatment for breast cancer all at the same time.

“This reduces the amount of time spent in hospital and enables women to recover more quickly, meaning they can get back to their lives more quickly.

“With publication of these very positive long-term results, it is now clear that this treatment should be made much more freely available. It should be accessible to healthcare providers and discussed with patients when surgery for breast cancer is being planned.”

Between March 2000 and June 2012, 1,140 patients were randomised to TARGIT-IORT and 1,158 to whole breast radiotherapy (EBRT).

At the five-year follow up, recurrence risk of localised breast cancer was 2.1% (24/1140 patients) for TARGIT-IORT compared to 0.95% (11/1158 patients) for EBRT. This difference (1.16%) in recurrence risk is very small and clinically insignificant, concluding that TARGIT-IORT is non-inferior to EBRT. There were 14 fewer deaths (42/1140 v 56/1158) for TARGIT-IORT compared with EBRT.

Significantly, at long-term follow up (average 8.6 years, maximum 18.9 years) there was no statistically significant difference found in any of the breast cancer outcomes, and there was a substantial reduction in deaths from causes other than breast cancer with TARGIT-IORT.

Co-author, Professor Michael Baum (UCL surgery & interventional science), said: “These results are the highest level of evidence proving not only the effectiveness of TARGIT-IORT but confirming that it avoids deaths from other causes. I am pleased that it will benefit thousands of breast cancer patients around the world.”

Co-author, Professor Jeffrey S Tobias (professor of clinical sncology, UCL & UCLH) said: “With TARGIT-IORT, a large proportion of patients with breast cancer will never need to make the repeated daily visits to the radiotherapy centre. They avoid side effects of whole breast radiotherapy. Importantly, TARGIT-IORT reduces the burden on overstretched radiotherapy departments.”

The TARGIT-IORT technique was developed by clinical academics, Vaidya, Tobias and Baum, in 1998 in collaboration with the manufacturers. During the past 20 years this method has been used worldwide in over 260 medical health centres in 38 countries, helping to treat more than 45,000 patients.

Funding for the trial was provided by the National Institute for Health Research (NIHR) Health Technology Assessment programme, UCL Comprehensive Biomedical Research Centre, and Cancer Research UK.

 

 

Mia Rosenblatt, assistant director of policy and campaigns at the charity Breast Cancer Now, said in a report in The Guardian that the research was encouraging and confirmed that the treatment could cut women’s visits to hospital and reduce the side-effects of radiotherapy.

But more work needed to be done to help fine-tune the selection of women who have single-dose radiotherapy, because some in the study needed extra traditional radiotherapy as well. In addition, some hospitals are now offering a five-dose alternative to the conventional weeks-long option, so the benefits of single-dose treatment compared with that needed to be assessed, she added.

Abstract
Objective: To determine whether risk adapted intraoperative radiotherapy, delivered as a single dose during lumpectomy, can effectively replace postoperative whole breast external beam radiotherapy for early breast cancer.
Design: Prospective, open label, randomised controlled clinical trial.
Setting: 32 centres in 10 countries in the United Kingdom, Europe, Australia, the United States, and Canada.
Participants: 2298 women aged 45 years and older with invasive ductal carcinoma up to 3.5 cm in size, cN0-N1, eligible for breast conservation and randomised before lumpectomy (1:1 ratio, blocks stratified by centre) to either risk adapted targeted intraoperative radiotherapy (TARGIT-IORT) or external beam radiotherapy (EBRT).
Interventions: Random allocation was to the EBRT arm, which consisted of a standard daily fractionated course (three to six weeks) of whole breast radiotherapy, or the TARGIT-IORT arm. TARGIT-IORT was given immediately after lumpectomy under the same anaesthetic and was the only radiotherapy for most patients (around 80%). TARGIT-IORT was supplemented by EBRT when postoperative histopathology found unsuspected higher risk factors (around 20% of patients).
Main outcome measures: Non-inferiority with a margin of 2.5% for the absolute difference between the five-year local recurrence rates of the two arms, and long term survival outcomes.
Results: Between 24 March 2000 and 25 June 2012, 1140 patients were randomised to TARGIT-IORT and 1158 to EBRT. TARGIT-IORT was non-inferior to EBRT: the local recurrence risk at five year complete follow-up was 2.11% for TARGIT-IORT compared with 0.95% for EBRT (difference 1.16%, 90% confidence interval 0.32 to 1.99). In the first five years, 13 additional local recurrences were reported (24/1140 v 11/1158) but 14 fewer deaths (42/1140 v 56/1158) for TARGIT-IORT compared with EBRT. With long term follow-up (median 8.6 years, maximum 18.90 years, interquartile range 7.0-10.6) no statistically significant difference was found for local recurrence-free survival (hazard ratio 1.13, 95% confidence interval 0.91 to 1.41, P=0.28), mastectomy-free survival (0.96, 0.78 to 1.19, P=0.74), distant disease-free survival (0.88, 0.69 to 1.12, P=0.30), overall survival (0.82, 0.63 to 1.05, P=0.13), and breast cancer mortality (1.12, 0.78 to 1.60, P=0.54). Mortality from other causes was significantly lower (0.59, 0.40 to 0.86, P=0.005).
Conclusion: For patients with early breast cancer who met our trial selection criteria, risk adapted immediate single dose TARGIT-IORT during lumpectomy was an effective alternative to EBRT, with comparable long term efficacy for cancer control and lower non-breast cancer mortality. TARGIT-IORT should be discussed with eligible patients when breast conserving surgery is planned.

Authors
Norman R Williams, Ingrid Potyka, Nicholas Roberts, Marcelle Bernstein, Douglas Brown, Elena Sperk, Siobhan Laws, Marc Sütterlin, Tammy Corica, Steinar Lundgren, Dennis Holmes, Lorenzo Vinante, Fernando Bozza, Montserrat Pazos, Magali Le Blanc-Onfroy, Günther Gruber, Wojciech Polkowski, Konstantin J Dedes, Marcus Niewald, Jens Blohmer, David McCready, Richard Hoefer, Pond Kelemen, Gloria Petralia, Mary Falzon, David J Joseph, Jeffrey S Tobias

 

University College London material

 

BMJ abstract

 

Full report in The Guardian

Receive Medical Brief's free weekly e-newsletter



Related Posts

Thank you for subscribing to MedicalBrief


MedicalBrief is Africa’s premier medical news and research weekly newsletter. MedicalBrief is published every Thursday and delivered free of charge by email to over 33 000 health professionals.

Please consider completing the form below. The information you supply is optional and will only be used to compile a demographic profile of our subscribers. Your personal details will never be shared with a third party.


Thank you for taking the time to complete the form.